References
Query Results -- Details
MGI Accession ID: MGI:3621605
J Number: J:107656
Other Accession IDs:
Title: Galectin-3 regulates myofibroblast activation and hepatic fibrosis.
Authors: Henderson NC; Mackinnon AC; Farnworth SL; Poirier F; Russo FP; Iredale JP; Haslett C; Simpson KJ; Sethi T
Journal: Proc Natl Acad Sci U S A
Volume: 103
Issue: 13
Date: 2006 Mar 28
Year: 2006
Pages: 5060-5
Review Status: Peer Reviewed
Abstract:
Central to fibrogenesis and the scarring of organs is the activation of fibroblasts into matrix-secreting myofibroblasts. We demonstrate that Galectin-3 expression is up-regulated in established human fibrotic liver disease and is temporally and spatially related to the induction and resolution of experimental hepatic fibrosis. Disruption of the Galectin-3 gene blocks myofibroblast activation and procollagen (I) expression in vitro and in vivo, markedly attenuating liver fibrosis. Addition of exogenous recombinant Galectin-3 in vitro reversed this abnormality. The reduction in hepatic fibrosis observed in the Galectin-3(-/-) mouse occurred despite equivalent liver injury and inflammation, and similar tissue expression of TGF-beta. TGF-beta failed to transactivate Galectin-3(-/-) hepatic stellate cells, in contrast with WT hepatic stellate cells; however, TGF-beta-stimulated Smad-2 and -3 activation was equivalent. These data suggest that Galectin-3 is required for TGF-beta mediated myofibroblast activation and matrix production. Finally, in vivo siRNA knockdown of Galectin-3 inhibited myofibroblast activation after hepatic injury and may therefore provide an alternative therapeutic approach to the prevention and treatment of liver fibrosis.
Additional Information:
